SCHEMBL6534808

SCHEMBL6534808

CCCOCc1cc(C(=O)C(=O)O)c2c3c(C(N)=O)cccc3n(Cc3ccccc3)c2c1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 18/20 0.43
PLA2G10 O15496 3/20 0.40
PLA2G1B P04054 3/20 0.40
PLA2G5 P39877 3/20 0.40
PLA2G2E Q9NZK7 3/20 0.40
PLA2G2F Q9BZM2 2/20 0.39
PLA2G2D Q9UNK4 2/20 0.39
PLA2G6 O60733 1/20 0.39
PLA2G2C Q5R387 1/20 0.39
PLA2G12B Q9BX93 1/20 0.39
PLA2G12A Q9BZM1 1/20 0.39
PLA2G3 Q9NZ20 1/20 0.39
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8053026 0.91 PLA2G2A (0.42) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL27862244 0.86 PLA2G2A (0.39) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL819162 0.85 PLA2G2A (0.49) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL6534810 0.84 PLA2G2A (0.39) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL29862577 0.84 PLA2G2A (0.42) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL6129596 0.84 PPARG (0.45) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL6129647 0.81 PLA2G2A (0.50) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL8575180 0.81 PLA2G2A (0.46) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL6129640 0.79 SERPINE1 (0.49) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E
SCHEMBL6129600 0.79 PLA2G2A (0.45) PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1011670-A4 METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS LILLY CO ELI (US) 2004-10-27 EP claimed
JP-2004503586-A 2004-02-05 JP claimed
EP-1303262-A2 USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS ELI LILLY AND COMPANY (US) 2003-04-23 EP claimed
WO-2002005796-A2 USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS ELI LILLY AND COMPANY (US) 2002-01-24 WO claimed
EP-1011670-A1 METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS ELI LILLY AND COMPANY (US) 2000-06-28 EP claimed
WO-1999009978-A1 METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS ELI LILLY AND COMPANY (US) 1999-03-04 WO claimed
EP-1259260-A1 COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES ELI LILLY AND COMPANY (US) 2002-11-27 EP disclosed
EP-1214041-A2 COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS ELI LILLY AND COMPANY (US) 2002-06-19 EP disclosed
WO-2001055108-A2 USE OF SPL A2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION ELI LILLY AND COMPANY (US) 2001-08-02 WO disclosed
WO-2001049323-A1 COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES ELI LILLY AND COMPANY (US) 2001-07-12 WO disclosed
WO-2000037022-A2 COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS ELI LILLY AND COMPANY (US) 2000-06-29 WO disclosed